Blood Adv 2025 Feb 19
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.
Related Questions
As the cost of NGS decreases over time, is there still a need for more focused/targeted panels such as JAK2, CALR, and MPL? Are other genes important ...